Cargando…

PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales:	Pan, Pan, Pang, Aiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428819/ http://dx.doi.org/10.1097/01.HS9.0000976408.35913.80

Ejemplares similares

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

PB2452: PREVALENCE AND SEVERITY OF COVID-19 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS IN CHINA
por: Gao, Hongye, et al.
Publicado: (2023)

PB2451: EVALUATION OF PLATELET PARAMETERS IN PATIENTS WITH SECONDARY FAILURE OF PLATELET RECOVERY AND CYTOMEGALOVIRUS INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Cao, Yigeng, et al.
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY
por: Åkesson, A., et al.
Publicado: (2022)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
por: Chang, H., et al.
Publicado: (2022)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
por: Cai, Xuan, et al.
Publicado: (2022)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2589: EFFICACY AND SAFETY OF ABCD IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS WITH HEMATOLOGIC DISEASES
por: Pang, Aiming, et al.
Publicado: (2023)

PB1947: ELTROMBOPAG COMBINED WITH IST AS A MULTICENTER STUDY OF THE FIRST LINE TREATMENT OF CHILDREN WITH SAA.
por: Yang, L., et al.
Publicado: (2022)

PB2311: LOW-DOSE PREDNISON AND ELTROMBOPAG COMBINATION AS FRONTLINE TREATMENT IN NEWLY DIAGNOSED ITP PATIENTS
por: Liu, S.-Y., et al.
Publicado: (2022)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
por: Liu, Xiaoqing, et al.
Publicado: (2023)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
por: Sayed, Nesrine Ben, et al.
Publicado: (2023)

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
por: Zhang, Zhuxin, et al.
Publicado: (2023)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
por: Li, R., et al.
Publicado: (2022)

PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
por: Catania, Federica, et al.
Publicado: (2023)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
por: Ji, Jiang, et al.
Publicado: (2023)

PB2181: DOES SARCOPENIA INFLUENCE THE SUCCESS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Erdogan Yucel, E., et al.
Publicado: (2022)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
por: Zhu, Qiuhua, et al.
Publicado: (2021)

PB2199: A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Xu, J., et al.
Publicado: (2022)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
por: Bhat, Vivek, et al.
Publicado: (2023)

PB2338: QUALITY OF LIFE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF CHRONIC GVHD
por: Belloumi, D., et al.
Publicado: (2022)

PB2474: CONSTRUCTION OF NURSING SCHEME FOR PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREPARE FOR DISCHARGE
por: Wang, LI, et al.
Publicado: (2023)

PB2448: RESTORATION OF HEMOGRAM PARAMETERS IN PATIENTS WITH HEMOBLASTOSIS AFTER TRANSPLANTATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS
por: Natalia, Isaeva, et al.
Publicado: (2023)

PB2573: MICRORNA CLUSTERS FACILITATE THE PREDICTION OF INFECTIOUS FEVER AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Liu, LI, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2436: EFFICACY AND SAFETY PROFILE OF EVEROLIMUS AS A MAINTENANCE THERAPY FOR PRIMARY REFRACTORY/RELAPSING HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Zamani, Shayan, et al.
Publicado: (2023)

PB2315: EFFICACY AND SAFETY OF TWO DIFFERENT LOW-DOSE RITUXIMAB REGIMENS FOR CHINESE CHILDREN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
por: Zhu, X.
Publicado: (2022)

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
por: Tsykunova, G., et al.
Publicado: (2022)

PB2007: FACTORS ASSOCIATED WITH EARLY RELAPSE IN MYELOMA PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Karatas, A., et al.
Publicado: (2022)

PB2418: CLINICAL FEATURES AND PROGNOSIS OF ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Sun, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8obkucl49iltvqlo1ijgijkjf4